Читать книгу Protocols for High-Risk Pregnancies - Группа авторов - Страница 37

1 Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization – United States, 1999–2014. MMWR 2018; 67:845–9.

2 Kotelchuck M, Cheng ER, Belanoff C, et al. The prevalence and impact of substance use disorder and treatment on maternal obstetric experiences and birth outcomes among singleton deliveries in Massachusetts. Matern Child Health J 2017; 21(4):893–902.

3 Ondersma SJ, Chang G, Blake‐Lamb T, et al. Accuracy of five self‐report screening instruments for substance use in pregnancy. Addiction 2019; 114(9):1683–93.

4 Schiff DM, Nielsen T, Terplan M, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol 2018; 132(2):466–74.

5 Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18‐5054. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.

6 Terplan M. Women and the opioid crisis: historical context and public health solutions. Fertil Steril 2017; 108(2):195–9.

7 Terplan M, Kennedy‐Hendricks A, Chisolm MS. Prenatal substance use: exploring assumptions of maternal unfitness. Subst Abuse 2015; 9(Suppl 2):1–4.

8 Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156(4):569–76.

9 Wachman EM, Hayes MJ, Lester BM, Terrin N, Brown MS, Davis JM. Epigenetic variation in the mu‐opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 2014; 165(3):472–8.